EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy

G. J. Sturm, E. M. Varga, G. Roberts, H. Mosbech, M. B. Bilò, C. A. Akdis, D. Antolín-Amérigo, E. Cichocka-Jarosz, R. Gawlik, T. Jakob, M. Kosnik, J. Lange, E. Mingomataj, D. I. Mitsias, M. Ollert, J. N.G. Oude Elberink, O. Pfaar, C. Pitsios, V. Pravettoni, F. RuëffB. A. Sin, I. Agache, E. Angier, S. Arasi, M. A. Calderón, M. Fernandez-Rivas, S. Halken, M. Jutel, S. Lau, G. B. Pajno, R. van Ree, D. Ryan, O. Spranger, R. G. van Wijk, S. Dhami, H. Zaman, A. Sheikh, A. Muraro

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Hymenoptera venom allergy is a potentially life-threatening allergic reaction following a honeybee, vespid, or ant sting. Systemic-allergic sting reactions have been reported in up to 7.5% of adults and up to 3.4% of children. They can be mild and restricted to the skin or moderate to severe with a risk of life-threatening anaphylaxis. Patients should carry an emergency kit containing an adrenaline autoinjector, H1-antihistamines, and corticosteroids depending on the severity of their previous sting reaction(s). The only treatment to prevent further systemic sting reactions is venom immunotherapy. This guideline has been prepared by the European Academy of Allergy and Clinical Immunology's (EAACI) Taskforce on Venom Immunotherapy as part of the EAACI Guidelines on Allergen Immunotherapy initiative. The guideline aims to provide evidence-based recommendations for the use of venom immunotherapy, has been informed by a formal systematic review and meta-analysis and produced using the Appraisal of Guidelines for Research and Evaluation (AGREE II) approach. The process included representation from a range of stakeholders. Venom immunotherapy is indicated in venom-allergic children and adults to prevent further moderate-to-severe systemic sting reactions. Venom immunotherapy is also recommended in adults with only generalized skin reactions as it results in significant improvements in quality of life compared to carrying an adrenaline autoinjector. This guideline aims to give practical advice on performing venom immunotherapy. Key sections cover general considerations before initiating venom immunotherapy, evidence-based clinical recommendations, risk factors for adverse events and for relapse of systemic sting reaction, and a summary of gaps in the evidence.

Original languageEnglish
Pages (from-to)744-764
JournalAllergy: European Journal of Allergy and Clinical Immunology
Volume73
Issue number4
DOIs
Publication statusPublished - 2018

Fingerprint

Immunologic Desensitization
Hymenoptera
Venoms
Allergy and Immunology
Hypersensitivity
Immunotherapy
Guidelines
Bites and Stings
Epinephrine
Skin
Ants
Histamine Antagonists
Anaphylaxis
Meta-Analysis
Adrenal Cortex Hormones
Emergencies
Quality of Life
Recurrence

Keywords

  • Anaphylaxis
  • Effectiveness
  • Hymenoptera venom allergy
  • Safety
  • Venom immunotherapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Sturm, G. J., Varga, E. M., Roberts, G., Mosbech, H., Bilò, M. B., Akdis, C. A., ... Muraro, A. (2018). EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy. Allergy: European Journal of Allergy and Clinical Immunology, 73(4), 744-764. https://doi.org/10.1111/all.13262

EAACI guidelines on allergen immunotherapy : Hymenoptera venom allergy. / Sturm, G. J.; Varga, E. M.; Roberts, G.; Mosbech, H.; Bilò, M. B.; Akdis, C. A.; Antolín-Amérigo, D.; Cichocka-Jarosz, E.; Gawlik, R.; Jakob, T.; Kosnik, M.; Lange, J.; Mingomataj, E.; Mitsias, D. I.; Ollert, M.; Oude Elberink, J. N.G.; Pfaar, O.; Pitsios, C.; Pravettoni, V.; Ruëff, F.; Sin, B. A.; Agache, I.; Angier, E.; Arasi, S.; Calderón, M. A.; Fernandez-Rivas, M.; Halken, S.; Jutel, M.; Lau, S.; Pajno, G. B.; van Ree, R.; Ryan, D.; Spranger, O.; van Wijk, R. G.; Dhami, S.; Zaman, H.; Sheikh, A.; Muraro, A.

In: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 73, No. 4, 2018, p. 744-764.

Research output: Contribution to journalArticle

Sturm, GJ, Varga, EM, Roberts, G, Mosbech, H, Bilò, MB, Akdis, CA, Antolín-Amérigo, D, Cichocka-Jarosz, E, Gawlik, R, Jakob, T, Kosnik, M, Lange, J, Mingomataj, E, Mitsias, DI, Ollert, M, Oude Elberink, JNG, Pfaar, O, Pitsios, C, Pravettoni, V, Ruëff, F, Sin, BA, Agache, I, Angier, E, Arasi, S, Calderón, MA, Fernandez-Rivas, M, Halken, S, Jutel, M, Lau, S, Pajno, GB, van Ree, R, Ryan, D, Spranger, O, van Wijk, RG, Dhami, S, Zaman, H, Sheikh, A & Muraro, A 2018, 'EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy', Allergy: European Journal of Allergy and Clinical Immunology, vol. 73, no. 4, pp. 744-764. https://doi.org/10.1111/all.13262
Sturm, G. J. ; Varga, E. M. ; Roberts, G. ; Mosbech, H. ; Bilò, M. B. ; Akdis, C. A. ; Antolín-Amérigo, D. ; Cichocka-Jarosz, E. ; Gawlik, R. ; Jakob, T. ; Kosnik, M. ; Lange, J. ; Mingomataj, E. ; Mitsias, D. I. ; Ollert, M. ; Oude Elberink, J. N.G. ; Pfaar, O. ; Pitsios, C. ; Pravettoni, V. ; Ruëff, F. ; Sin, B. A. ; Agache, I. ; Angier, E. ; Arasi, S. ; Calderón, M. A. ; Fernandez-Rivas, M. ; Halken, S. ; Jutel, M. ; Lau, S. ; Pajno, G. B. ; van Ree, R. ; Ryan, D. ; Spranger, O. ; van Wijk, R. G. ; Dhami, S. ; Zaman, H. ; Sheikh, A. ; Muraro, A. / EAACI guidelines on allergen immunotherapy : Hymenoptera venom allergy. In: Allergy: European Journal of Allergy and Clinical Immunology. 2018 ; Vol. 73, No. 4. pp. 744-764.
@article{f5aca775c40540c098fad803d207a05e,
title = "EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy",
abstract = "Hymenoptera venom allergy is a potentially life-threatening allergic reaction following a honeybee, vespid, or ant sting. Systemic-allergic sting reactions have been reported in up to 7.5{\%} of adults and up to 3.4{\%} of children. They can be mild and restricted to the skin or moderate to severe with a risk of life-threatening anaphylaxis. Patients should carry an emergency kit containing an adrenaline autoinjector, H1-antihistamines, and corticosteroids depending on the severity of their previous sting reaction(s). The only treatment to prevent further systemic sting reactions is venom immunotherapy. This guideline has been prepared by the European Academy of Allergy and Clinical Immunology's (EAACI) Taskforce on Venom Immunotherapy as part of the EAACI Guidelines on Allergen Immunotherapy initiative. The guideline aims to provide evidence-based recommendations for the use of venom immunotherapy, has been informed by a formal systematic review and meta-analysis and produced using the Appraisal of Guidelines for Research and Evaluation (AGREE II) approach. The process included representation from a range of stakeholders. Venom immunotherapy is indicated in venom-allergic children and adults to prevent further moderate-to-severe systemic sting reactions. Venom immunotherapy is also recommended in adults with only generalized skin reactions as it results in significant improvements in quality of life compared to carrying an adrenaline autoinjector. This guideline aims to give practical advice on performing venom immunotherapy. Key sections cover general considerations before initiating venom immunotherapy, evidence-based clinical recommendations, risk factors for adverse events and for relapse of systemic sting reaction, and a summary of gaps in the evidence.",
keywords = "Anaphylaxis, Effectiveness, Hymenoptera venom allergy, Safety, Venom immunotherapy",
author = "Sturm, {G. J.} and Varga, {E. M.} and G. Roberts and H. Mosbech and Bil{\`o}, {M. B.} and Akdis, {C. A.} and D. Antol{\'i}n-Am{\'e}rigo and E. Cichocka-Jarosz and R. Gawlik and T. Jakob and M. Kosnik and J. Lange and E. Mingomataj and Mitsias, {D. I.} and M. Ollert and {Oude Elberink}, {J. N.G.} and O. Pfaar and C. Pitsios and V. Pravettoni and F. Ru{\"e}ff and Sin, {B. A.} and I. Agache and E. Angier and S. Arasi and Calder{\'o}n, {M. A.} and M. Fernandez-Rivas and S. Halken and M. Jutel and S. Lau and Pajno, {G. B.} and {van Ree}, R. and D. Ryan and O. Spranger and {van Wijk}, {R. G.} and S. Dhami and H. Zaman and A. Sheikh and A. Muraro",
year = "2018",
doi = "10.1111/all.13262",
language = "English",
volume = "73",
pages = "744--764",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - EAACI guidelines on allergen immunotherapy

T2 - Hymenoptera venom allergy

AU - Sturm, G. J.

AU - Varga, E. M.

AU - Roberts, G.

AU - Mosbech, H.

AU - Bilò, M. B.

AU - Akdis, C. A.

AU - Antolín-Amérigo, D.

AU - Cichocka-Jarosz, E.

AU - Gawlik, R.

AU - Jakob, T.

AU - Kosnik, M.

AU - Lange, J.

AU - Mingomataj, E.

AU - Mitsias, D. I.

AU - Ollert, M.

AU - Oude Elberink, J. N.G.

AU - Pfaar, O.

AU - Pitsios, C.

AU - Pravettoni, V.

AU - Ruëff, F.

AU - Sin, B. A.

AU - Agache, I.

AU - Angier, E.

AU - Arasi, S.

AU - Calderón, M. A.

AU - Fernandez-Rivas, M.

AU - Halken, S.

AU - Jutel, M.

AU - Lau, S.

AU - Pajno, G. B.

AU - van Ree, R.

AU - Ryan, D.

AU - Spranger, O.

AU - van Wijk, R. G.

AU - Dhami, S.

AU - Zaman, H.

AU - Sheikh, A.

AU - Muraro, A.

PY - 2018

Y1 - 2018

N2 - Hymenoptera venom allergy is a potentially life-threatening allergic reaction following a honeybee, vespid, or ant sting. Systemic-allergic sting reactions have been reported in up to 7.5% of adults and up to 3.4% of children. They can be mild and restricted to the skin or moderate to severe with a risk of life-threatening anaphylaxis. Patients should carry an emergency kit containing an adrenaline autoinjector, H1-antihistamines, and corticosteroids depending on the severity of their previous sting reaction(s). The only treatment to prevent further systemic sting reactions is venom immunotherapy. This guideline has been prepared by the European Academy of Allergy and Clinical Immunology's (EAACI) Taskforce on Venom Immunotherapy as part of the EAACI Guidelines on Allergen Immunotherapy initiative. The guideline aims to provide evidence-based recommendations for the use of venom immunotherapy, has been informed by a formal systematic review and meta-analysis and produced using the Appraisal of Guidelines for Research and Evaluation (AGREE II) approach. The process included representation from a range of stakeholders. Venom immunotherapy is indicated in venom-allergic children and adults to prevent further moderate-to-severe systemic sting reactions. Venom immunotherapy is also recommended in adults with only generalized skin reactions as it results in significant improvements in quality of life compared to carrying an adrenaline autoinjector. This guideline aims to give practical advice on performing venom immunotherapy. Key sections cover general considerations before initiating venom immunotherapy, evidence-based clinical recommendations, risk factors for adverse events and for relapse of systemic sting reaction, and a summary of gaps in the evidence.

AB - Hymenoptera venom allergy is a potentially life-threatening allergic reaction following a honeybee, vespid, or ant sting. Systemic-allergic sting reactions have been reported in up to 7.5% of adults and up to 3.4% of children. They can be mild and restricted to the skin or moderate to severe with a risk of life-threatening anaphylaxis. Patients should carry an emergency kit containing an adrenaline autoinjector, H1-antihistamines, and corticosteroids depending on the severity of their previous sting reaction(s). The only treatment to prevent further systemic sting reactions is venom immunotherapy. This guideline has been prepared by the European Academy of Allergy and Clinical Immunology's (EAACI) Taskforce on Venom Immunotherapy as part of the EAACI Guidelines on Allergen Immunotherapy initiative. The guideline aims to provide evidence-based recommendations for the use of venom immunotherapy, has been informed by a formal systematic review and meta-analysis and produced using the Appraisal of Guidelines for Research and Evaluation (AGREE II) approach. The process included representation from a range of stakeholders. Venom immunotherapy is indicated in venom-allergic children and adults to prevent further moderate-to-severe systemic sting reactions. Venom immunotherapy is also recommended in adults with only generalized skin reactions as it results in significant improvements in quality of life compared to carrying an adrenaline autoinjector. This guideline aims to give practical advice on performing venom immunotherapy. Key sections cover general considerations before initiating venom immunotherapy, evidence-based clinical recommendations, risk factors for adverse events and for relapse of systemic sting reaction, and a summary of gaps in the evidence.

KW - Anaphylaxis

KW - Effectiveness

KW - Hymenoptera venom allergy

KW - Safety

KW - Venom immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85037373305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037373305&partnerID=8YFLogxK

U2 - 10.1111/all.13262

DO - 10.1111/all.13262

M3 - Article

AN - SCOPUS:85037373305

VL - 73

SP - 744

EP - 764

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

SN - 0105-4538

IS - 4

ER -